July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

ARQ-151 meets Phase IIb endpoint
Arcutis Inc. (Westlake Village, Calif.) said high and low daily doses of ARQ-151 for six weeks met the primary endpoint in a Phase IIb

Read the full 286 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE